AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
37.78
-0.02 (-0.05%)
At close: 4:00PM EDT

37.41 -0.37 (-0.98%)
Pre-Market: 7:36AM EDT

Stock chart is not supported by your current browser
Previous Close37.80
Open37.63
Bid37.34 x 3200
Ask37.68 x 800
Day's Range37.58 - 37.91
52 Week Range34.38 - 43.30
Volume1,716,339
Avg. Volume5,424,290
Market Cap100.517B
Beta (3Y Monthly)0.47
PE Ratio (TTM)39.77
EPS (TTM)0.95
Earnings DateN/A
Forward Dividend & Yield1.40 (3.72%)
Ex-Dividend Date2019-02-28
1y Target Est46.10
Trade prices are not sourced from all markets
  • Rigel Initiates Enrollment in Pivotal Blood Disorder Study
    Zacks3 days ago

    Rigel Initiates Enrollment in Pivotal Blood Disorder Study

    Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

  • Business Wire4 days ago

    AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

    Data focused on breaking treatment boundaries, treating patients earlier in their disease, and raising the bar for better outcomes

  • 3 Top Diabetes Stocks to Watch in May
    Motley Fool5 days ago

    3 Top Diabetes Stocks to Watch in May

    These three diabetes stocks should be on your radar right now.

  • GuruFocus.com6 days ago

    AstraZeneca Needs New Breast Cancer Drug to be Blockbuster

    AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.

  • AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
    Zacks9 days ago

    AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark

    AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.

  • Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
    Zacks10 days ago

    Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

    Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

  • Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
    Zacks10 days ago

    Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

    Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

  • Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
    MarketWatch11 days ago

    Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices

    The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.

  • AstraZeneca Gets an $8 Billion Punishment
    Bloomberg11 days ago

    AstraZeneca Gets an $8 Billion Punishment

    AstraZeneca Plc’s first-ever stock sale has been a painful experience. The British drugmaker was exploiting its strong share price to get its financial house in order. Right now, its free cash flow isn’t enough to cover the dividend without some help from disposals.

  • Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
    Zacks12 days ago

    Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

    Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.

  • Business Wire12 days ago

    AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer

    AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can help patients and their physician find the treatment options that are right for them. AstraZeneca is partnering with the world-renowned golf pro to launch the Test It Back campaign, focused on ensuring complete biomarker testing becomes standard of care at every late-stage lung cancer diagnosis. The Test It Back site includes a series of inspiring videos featuring Day and his mother, Dening, whose decision to get mutation testing of her Stage IV non-small cell lung cancer last year informed her treatment decisions.

  • Guardant Health (GH) to Report Q1 Earnings: What's in Store?
    Zacks13 days ago

    Guardant Health (GH) to Report Q1 Earnings: What's in Store?

    At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

  • Business Wire17 days ago

    Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards

    The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards. The awards – a partnership between AstraZeneca and Scientific American Custom Media – includes nominations submitted by organizations from across the cancer ecosystem and participation from an esteemed panel of third-party judges. “There is so much progress happening in cancer care, but it takes a village to make real change,” expressed Olivier Nataf, Head of US Oncology, AstraZeneca.

  • Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
    Zacks17 days ago

    Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

    Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of AZN.L earnings conference call or presentation 26-Apr-19 11:00am GMT

    Q1 2019 AstraZeneca PLC Earnings Call

  • Benzinga18 days ago

    The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...

  • AstraZeneca’s Lynparza Gives a Strong Performance in Q1
    Market Realist18 days ago

    AstraZeneca’s Lynparza Gives a Strong Performance in Q1

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Lynparza’s first-quarter performance In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported

  • Reuters18 days ago

    AstraZeneca ties up with France's Transgene to develop viral immunotherapies

    Viral immunotherapy represents a new way of treating cancer by using transgenes, or genes that are artificially introduced into the genome of another organism. "AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialisation of these novel oncolytic immunotherapies," Transgene said. AstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.

  • AstraZeneca’s Imfinzi Maintains Strong Growth in Q1
    Market Realist19 days ago

    AstraZeneca’s Imfinzi Maintains Strong Growth in Q1

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Imfinzi’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Imfinzi saw sales of $295 million, mainly driven by its rapid uptake as an

  • AstraZeneca’s Tagrisso Sees the Fastest Growth in Q1
    Market Realist19 days ago

    AstraZeneca’s Tagrisso Sees the Fastest Growth in Q1

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Tagrisso’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis

  • BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery
    TechCrunch19 days ago

    BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery

    BenevolentAI is an AI company where AI actually means something. Founded in 2013, it focuses on "accelerating the journey from data to medicines." To achieve that, it has raised a whopping $202 million to look at early drug discovery through to late-stage clinical development, and has a research facility in Cambridge, U.K. where there is plenty of AI talent to be had. Today it has inked a long-term collaboration with pharma giant AstraZeneca to use AI and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

  • AstraZeneca’s Expense Guidance for Fiscal 2019
    Market Realist19 days ago

    AstraZeneca’s Expense Guidance for Fiscal 2019

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Expense guidanceIn its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low

  • An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued
    Simply Wall St.19 days ago

    An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for AstraZeneca PLC (LON:AZN) reflect what it's really worth? Today, we will...

  • What AstraZeneca Expects for EPS in Fiscal 2019
    Market Realist20 days ago

    What AstraZeneca Expects for EPS in Fiscal 2019

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)EPS guidance In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for core EPS of $3.50–$3.70 in fiscal 2019. The company expects its YoY

  • AstraZeneca Reiterates Its Fiscal 2019 Revenue Guidance
    Market Realist20 days ago

    AstraZeneca Reiterates Its Fiscal 2019 Revenue Guidance

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Revenue guidanceIn its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product